Diane Weiser
Senior Vice President of Corporate Affairs
Replay available
Cytokinetics, Incorporated (CYTK) Q2 2026 Earnings Call
Cytokinetics, Incorporated (NASDAQ: CYTK) Q2 2026 earnings conference call, held 2026-08-06. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Robert Blum
President and Chief Executive Officer
Andrew Callos
Executive Vice President and Chief Commercial Officer
Fady Malik
Executive Vice President, Research and Development
Steve Heitner
Senior Vice President and Chief Medical Officer
Sung Lee
Executive Vice President and Chief Financial Officer
Salim Syed
Analyst, Mizuho Securities
Rowana Ruiz
Analyst, Leerink Partners
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Cytokinetics, Incorporated.
Replay transcript excerpt
WEBVTT 00:00:00.051 -- 00:00:03.852 Thank you for standing by and welcome to the Psychokinetics 00:00:03.852 -- 00:00:08.893 Q2 2026 earnings conference call. This call is being recorded and all 00:00:08.893 -- 00:00:13.614 participants are in a listen only mode. After the speaker's remarks, we will open the 00:00:13.614 -- 00:00:18.335 call to questions. We will allow for one question per participant. 00:00:18.335 -- 00:00:23.337 If you would like to ask a question during this time, simply press star followed by the 00:00:23.337 -- 00:00:27.898 number one on your telephone keypad. If you would like to withdraw your question, press 00:00:27.898 -- 00:00:33.415 star one again. I would now like to turn the call over to Diane Weiser, Cytokinetics 00:00:33.415 -- 00:00:36.077 Senior Vice President of Corporate Affairs. 00:00:36.077 -- 00:00:38.957 Diane, please go ahead. 00:00:39.058 -- 00:00:42.320 Good afternoon and thanks for joining us on the call today. 00:00:42.320 -- 00:00:46.862 The slides accompanying today's webcast can be found on the Investors and Media section 00:00:46.862 -- 00:00:50.323 of our website at cytokinetics.com 00:00:50.524 -- 00:00:54.946 along with today's press release. Robert Blum, President and Chief Executive Officer, 00:00:54.946 -- 00:00:58.566 will begin with an overview of the quarter and recent developments. 00:00:58.566 -- 00:01:03.389 Andrew Callos, EVP and Chief Commercial Officer, will discuss the commercial launch of 00:01:03.389 -- 00:01:08.593 mycorrhizal in the U.S. and Europe. Fady Malik, EVP of R&D, will provide 00:01:08.593 -- 00:01:14.357 updates related to AfriCampden. Steve Heitner, SVP and Chief Medical Officer, 00:01:14.357 -- 00:01:18.620 will provide updates related to our ongoing clinical development programs. 00:01:...